Compare AAUC & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAUC | EWTX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | Canada | United States |
| Employees | 2252 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.3B |
| IPO Year | N/A | 2021 |
| Metric | AAUC | EWTX |
|---|---|---|
| Price | $31.11 | $31.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $37.38 |
| AVG Volume (30 Days) | 262.0K | ★ 721.7K |
| Earning Date | 03-31-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $82.23 | N/A |
| Revenue Next Year | $55.97 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.40 | $10.60 |
| 52 Week High | $32.08 | $31.82 |
| Indicator | AAUC | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.66 | 60.66 |
| Support Level | $30.99 | $26.91 |
| Resistance Level | $31.73 | N/A |
| Average True Range (ATR) | 0.33 | 1.50 |
| MACD | -0.13 | 0.11 |
| Stochastic Oscillator | 57.69 | 82.26 |
Allied Gold Corp is a company focused on gold mining activities in Africa. Allied has three mines and several development and exploration projects in Africa where it has operating experience. Operations are located in Cote d'Ivoire, Mali, and Ethiopia. The company expands and optimizes initiatives at existing operating mines, the development of new mines, the advancement of its exploration properties, and, targeting other consolidation opportunities with a focus on Africa.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.